



## Tracleer® (bosentan) – First-time generic

- [Amneal](#) and [Par/Endo](#) launched AB-rated generic versions of Actelion's [Tracleer \(bosentan\)](#) 62.5 mg and 125 mg tablets.
  - [Alvogen](#), [Lupin/Natco](#), [Sun](#), [Teva/Watson](#), [West-Ward](#), and [Zydus](#) have also received FDA approval of AB-rated generic versions of Tracleer tablets. Launch plans are pending for these generics.
- Tracleer is approved for the treatment of pulmonary arterial hypertension (WHO Group 1).
- Tracleer is also available as a brand 32 mg tablet for oral suspension and carries the same indication as the tablets.
- Tracleer carries a boxed warning for risks of hepatotoxicity and embryo-fetal toxicity.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.